Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
24-Week Results of a Blinded Phase 2b Dose-Ranging Study of Baricitinib, an Oral Janus Kinase 1/Januse Kinase 2 Inhibitor, in Combination with Traditional Disease Modifying Antirheumatic Drugs in Patients with Rheumatoid Arthritis. Annual Scientific Meeting of the American-College-of-Rheumatology (ACR) and Association-of-Rheumatology-Health-Professionals (ARHP) Genovese, M. C., Keystone, E., Taylor, P., Drescher, E., Berclaz, P., Lee, C. H., Schlichting, D. E., Beattie, S. D., Fidelus-Gort, R. K., Luchi, M. E., Macias, W. WILEY-BLACKWELL. 2012: S1049–S1050
View details for Web of Science ID 000309748305407